Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 6;8(3):317.
doi: 10.3390/jcm8030317.

Effectiveness of the Botulinum Toxin for Treating Sialorrhea in Patients with Parkinson's Disease: A Systematic Review

Juan Antonio Ruiz-Roca  1 , Eduardo Pons-Fuster  2 , Pia Lopez-Jornet  3
Affiliations
Review

Effectiveness of the Botulinum Toxin for Treating Sialorrhea in Patients with Parkinson's Disease: A Systematic Review

Juan Antonio Ruiz-Roca et al. J Clin Med. .

Abstract

The main objective was to assess the efficacy of botulinum toxin-based treatment for sialorrhea in adult patients with Parkinson's disease. The search was performed by using the Medline-PubMed, EMBASE and Cochrane Library databases from January 2000⁻December 2017, in English/Spanish in patients with Parkinson's disease and sialorrhea. The methodological quality of trials was carried out by following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria and the Newcastle⁻Ottawa Scale (NOS). Finally, a total of 21 articles were identified as fulfilling the inclusion criteria. There is no consensus regarding the site of injection of the toxin (single or multiple points), toxin dose or follow-up period. In all cases there was a reduction of sialorrhea. Treatment safety increases with the use of ultrasonography. Effects approximately occur at one week post-injection and for 3⁻5 months. Botulinum toxin is an effective therapeutic strategy or option in treating sialorrhea in adult patients with Parkinson's disease. More studies with a better design, larger samples and a longer follow-up period are required to confirm these data.

Keywords: Parkinson’s disease; botulinum toxin; drooling; sialorrhea.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Connolly B.S., Lang A.E. Pharmacological treatment of Parkinson disease: A review. JAMA. 2014;30:1670–1683. doi: 10.1001/jama.2014.3654. - DOI - PubMed
    1. Seppi K., Ray Chaudhuri K., Coelho M., Fox S.H., Katzenschlager R., Perez Lloret S., Weintraub D., Sampaio C., The collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov. Disord. 2019 doi: 10.1002/mds.27602. - DOI - PMC - PubMed
    1. Møller E., Karlsborg M., Bardow A., Lykkeaa J., Nissen F.H., Bakke M. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson’s disease: Efficacy and possible mechanisms. Acta Odontol. Scand. 2011;69:151–157. doi: 10.3109/00016357.2010.545035. - DOI - PubMed
    1. Bruno V.A., Fox S.H., Mancini D., Miyasaki J.M. Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism. Can. J. Neurol. Sci. 2016;43:697–702. doi: 10.1017/cjn.2016.279. - DOI - PubMed
    1. Cardoso F. Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections. Toxicon. 2018;147:107–110. doi: 10.1016/j.toxicon.2017.08.018. - DOI - PubMed

LinkOut - more resources